ATE538096T1 - Pyridinon-derivate zur behandlung von arteriosklerose - Google Patents

Pyridinon-derivate zur behandlung von arteriosklerose

Info

Publication number
ATE538096T1
ATE538096T1 AT01978400T AT01978400T ATE538096T1 AT E538096 T1 ATE538096 T1 AT E538096T1 AT 01978400 T AT01978400 T AT 01978400T AT 01978400 T AT01978400 T AT 01978400T AT E538096 T1 ATE538096 T1 AT E538096T1
Authority
AT
Austria
Prior art keywords
arteriosclerosis
treatment
pyridinone derivatives
pyridinone
derivatives
Prior art date
Application number
AT01978400T
Other languages
English (en)
Inventor
Deirdre HICKEY
Robert IFE
Colin LEACH
John Liddle
Ivan PINTO
Stephen Smith
Steven STANWAY
Original Assignee
Smithkline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Ltd filed Critical Smithkline Beecham Ltd
Application granted granted Critical
Publication of ATE538096T1 publication Critical patent/ATE538096T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01978400T 2000-10-10 2001-10-05 Pyridinon-derivate zur behandlung von arteriosklerose ATE538096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024808.8A GB0024808D0 (en) 2000-10-10 2000-10-10 Novel compounds
PCT/EP2001/011610 WO2002030904A1 (en) 2000-10-10 2001-10-05 Pyridinone derivatives for treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
ATE538096T1 true ATE538096T1 (de) 2012-01-15

Family

ID=9901006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01978400T ATE538096T1 (de) 2000-10-10 2001-10-05 Pyridinon-derivate zur behandlung von arteriosklerose

Country Status (28)

Country Link
US (2) US20040063753A1 (de)
EP (2) EP2258688B1 (de)
JP (1) JP4212354B2 (de)
KR (1) KR100824134B1 (de)
CN (2) CN1951917B (de)
AR (1) AR035349A1 (de)
AT (1) ATE538096T1 (de)
AU (2) AU1052402A (de)
BR (1) BRPI0114576B1 (de)
CA (1) CA2425268C (de)
CY (2) CY1112442T1 (de)
CZ (1) CZ304558B6 (de)
DK (2) DK1326841T3 (de)
ES (2) ES2378059T3 (de)
GB (1) GB0024808D0 (de)
GC (1) GC0000307A (de)
HU (1) HU230767B1 (de)
IL (2) IL155278A0 (de)
MX (1) MXPA03003176A (de)
MY (1) MY135766A (de)
NO (1) NO325107B1 (de)
NZ (1) NZ525225A (de)
PL (1) PL207560B1 (de)
PT (2) PT2258688E (de)
SI (2) SI1326841T1 (de)
TW (1) TWI293293B (de)
WO (1) WO2002030904A1 (de)
ZA (1) ZA200302785B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1263740T3 (da) * 2000-02-16 2006-11-13 Smithkline Beecham Plc Pyrimidin-4-on-derivat som LDL-PLA2-inhibitor
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US7741020B2 (en) 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) * 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
CN101687009A (zh) * 2007-05-11 2010-03-31 宾夕法尼亚大学理事会 治疗皮肤溃疡的方法
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
KR101730290B1 (ko) 2007-05-11 2017-04-25 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
US9512104B2 (en) 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8575348B2 (en) 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
WO2011049722A1 (en) * 2009-10-19 2011-04-28 Merck Sharp & Dohme Corp. PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS
EP2583099B1 (de) 2010-06-18 2016-11-02 Whitehead Institute for Biomedical Research Pla2g16 als target für antivirusverbindungen
KR101861883B1 (ko) * 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
JP2013544854A (ja) * 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
AR087309A1 (es) 2011-07-27 2014-03-12 Glaxo Group Ltd Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis
CA2842965A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
LT2751094T (lt) 2011-09-01 2018-11-12 Glaxo Group Limited Naujoji kristalinė forma
MX2015009633A (es) 2013-01-25 2015-11-30 Glaxosmithkline Ip Dev Ltd Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona.
US9296755B2 (en) 2013-01-25 2016-03-29 Glaxosmithkline Intellectual Property Development Limited 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications
EP2948456A4 (de) 2013-01-25 2016-09-14 Glaxosmithkline Ip Dev Ltd Bicyclische pyrimidonverbindungen als lp-pla2-hemmer
EP2764866A1 (de) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Hemmer der nedd8-aktivierenden Enzyme
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
EP4056571A4 (de) 2019-11-09 2024-01-24 Shanghai Simr Biotechnology Co., Ltd. Trizyklisches dihydroimidazopyrimidonderivat, verfahren zu seiner herstellung, pharmazeutische zusammensetzung und verwendung davon
CN112510260B (zh) * 2020-11-27 2022-11-04 珠海市赛纬电子材料股份有限公司 电解液添加剂、非水电解液和锂离子电池
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
WO2025015951A1 (zh) 2023-07-17 2025-01-23 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5769527A (en) 1986-07-17 1998-06-23 Vari-Lite, Inc. Computer controlled lighting system with distributed control resources
US5585246A (en) 1993-02-17 1996-12-17 Biometric Imaging, Inc. Method for preparing a sample in a scan capillary for immunofluorescent interrogation
EP0658205B1 (de) 1993-06-25 2000-03-15 Smithkline Beecham Plc An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
ATE315655T1 (de) 1993-10-06 2006-02-15 Icos Corp Acethylhydrolase des plättchen aktivierenden faktors
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
HUT77089A (hu) 1994-12-22 1998-03-02 Smithkline Beecham Plc. Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
CN1197452A (zh) 1995-07-01 1998-10-28 史密丝克莱恩比彻姆有限公司 用于治疗动脉粥样硬化的氮杂环丁烷酮衍生物
FR2743912B1 (fr) 1996-01-24 1998-04-10 Matra Communication Circuit de resolution d'equation-cle et decodeur reed-solomon incorporant un tel circuit
US5684794A (en) 1996-01-25 1997-11-04 Hazeltine Corporation Validation of subscriber signals in a cellular radio network
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
HUP0001140A3 (en) * 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
ES2203988T3 (es) * 1997-11-06 2004-04-16 Smithkline Beecham Plc Compuestos de pirimidinona y composiciones farmaceuticas que los contienen.
WO2000010980A1 (en) 1998-08-21 2000-03-02 Smithkline Beecham Plc Pyrimidinone derivatives for the treatment of atherosclerosis
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
KR20020012200A (ko) 1999-05-01 2002-02-15 피터 기딩스 피리미디논 화합물
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
JP4212354B2 (ja) 2009-01-21
ES2378059T3 (es) 2012-04-04
KR20030036916A (ko) 2003-05-09
US7235566B2 (en) 2007-06-26
HK1144941A1 (en) 2011-03-18
ES2399325T3 (es) 2013-03-27
EP1326841A1 (de) 2003-07-16
HUP0302480A2 (hu) 2003-12-29
CZ304558B6 (cs) 2014-07-09
BRPI0114576B1 (pt) 2017-05-30
NO325107B1 (no) 2008-02-04
DK1326841T3 (da) 2012-02-27
IL155278A (en) 2015-05-31
GC0000307A (en) 2006-11-01
MY135766A (en) 2008-06-30
SI1326841T1 (sl) 2012-04-30
MXPA03003176A (es) 2003-07-14
EP1326841B1 (de) 2011-12-21
AU1052402A (en) 2002-04-22
US20050014793A1 (en) 2005-01-20
SI2258688T1 (sl) 2013-03-29
CA2425268A1 (en) 2002-04-18
US20040063753A1 (en) 2004-04-01
NZ525225A (en) 2004-10-29
BR0114576A (pt) 2004-07-27
NO20031626L (no) 2003-06-04
CY1113648T1 (el) 2016-06-22
HUP0302480A3 (en) 2010-03-29
PT1326841E (pt) 2012-03-08
CN1479724A (zh) 2004-03-03
PL366334A1 (en) 2005-01-24
NO20031626D0 (no) 2003-04-09
IL155278A0 (en) 2003-11-23
CZ20031009A3 (cs) 2003-11-12
CA2425268C (en) 2011-09-13
CY1112442T1 (el) 2015-12-09
ZA200302785B (en) 2004-07-09
GB0024808D0 (en) 2000-11-22
HK1058036A1 (en) 2004-04-30
CN1951917A (zh) 2007-04-25
HU230767B1 (hu) 2018-03-28
TWI293293B (en) 2008-02-11
AU2002210524B2 (en) 2004-06-03
KR100824134B1 (ko) 2008-04-21
EP2258688A1 (de) 2010-12-08
DK2258688T3 (da) 2013-02-04
PT2258688E (pt) 2013-02-04
JP2004512283A (ja) 2004-04-22
PL207560B1 (pl) 2011-01-31
AR035349A1 (es) 2004-05-12
WO2002030904A1 (en) 2002-04-18
EP2258688B1 (de) 2012-11-21
CN1951917B (zh) 2012-07-18
CN1280275C (zh) 2006-10-18

Similar Documents

Publication Publication Date Title
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE60011570D1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60019195D1 (de) Behandlung durch Ablation von Knochenmetastasen
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
NO20031626L (no) Pyridonderivater for behandling av atherosklerose
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE279386T1 (de) Retinoide zur behandlung von emphysem
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
EP1117431A4 (de) Behandlung von acidose
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE60103685D1 (de) Behandlung von Poriomania
DE60026821D1 (de) Behandlung von bohrspülung